OR WAIT null SECS
CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.
At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of the Survivorship Program at Dana-Farber Cancer Center, about the progression and survival outcomes patient patients with metastatic castration-resistant prostate cancer at different time points throughout the phase 4 CARD trial (NCT02485691). Patients who enrolled on the trial were treated with either cabazitaxel (Jevtana) or a second androgen receptor inhibitor such as abiraterone (Zytiga) or enzalutamide (Xtandi) in order to compare costs and complications.
Interestingly, we found over time that the outcomes changed such that shorter term outcomes, [such as] progression decreased over the course of the study because at some point, patients did experience progression. The survival outcomes increased by the end of our follow-up period, as we really solidified mortality for some patients who had those unfortunate events. Ultimately, the reason we chose 18 months is that it was a nice time point to try to get a balanced picture. Between the 6-month shorter time points, and then our longer-term time points, it was just a nice place to report our primary findings.
Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract 587P.